PVG Escalates Proxy Fight With New Video Alleging Former CEO Lawsuits and Grant Termination
AVXL sits 27% above its 52-week low of $2.255.
Summary
PVG Asset Management posted a revised proxy video adding new allegations: the former CEO has filed an arbitration claim and a lawsuit against four directors, and the Michael J. Fox Foundation grant was terminated with $800,000 returned. The video escalates the boardroom battle ahead of the September 24 shareholder vote.
Key Events · Corporate Governance and Compliance · AVXL
-
PVG Posts Revised Proxy Video
PVG Asset Management amended and restated its proxy video on September 1, 2026, adding new allegations against Anavex's board and management.
-
Former CEO Files Legal Claims
The video discloses the former CEO filed an arbitration claim for wrongful termination and a lawsuit against four independent directors for breach of fiduciary duty.
-
Michael J. Fox Grant Terminated
Anavex disclosed the termination of the Michael J. Fox Foundation grant and is returning approximately $800,000, removing non-dilutive funding for the Parkinson's program.
-
Interim CEO Qualifications Attacked
PVG alleges the interim CEO has never held a CEO role, continues as Strategic Advisor to Aardvark Therapeutics, and oversaw a Phase 3 trial pause at that company in February 2026.
Analysis · AVXL · Life Sciences
Activist investor PVG Asset Management has escalated its proxy contest against Anavex Life Sciences with a revised video that adds new, material allegations. The video discloses that the former CEO has filed an arbitration claim for wrongful termination and a lawsuit against four independent directors for breach of fiduciary duty — legal actions that could create significant liabilities for the company. It also reveals the termination of the Michael J. Fox Foundation grant and the return of approximately $800,000, which removes non-dilutive funding for the Parkinson's program. The video further attacks the interim CEO's qualifications, noting her concurrent advisory role at Aardvark Therapeutics and the Phase 3 HERO trial pause at that company. These disclosures come just three weeks before the September 24 annual meeting where shareholders will vote on competing board slates. The proxy contest itself is highly material to Anavex's future direction, and the new legal and funding disclosures add concrete financial and governance risks to the story.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVXL was trading at $2.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $267.9M. The 52-week trading range was $2.26 to $10.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.